title: The impact of therapeutic reference pricing on innovation in cardiovascular medicine.
abstract: Therapeutic reference pricing (TRP) places medicines to treat the same medical condition into groups or 'clusters' with a single common reimbursed price. Underpinning this economic measure is an implicit assumption that the products included in the cluster have an equivalent effect on a typical patient with this disease. 'Truly innovative' products can be exempt from inclusion in the cluster. This increasingly common approach to cost containment allocates products into one of two categories - truly innovative or therapeutically equivalent. This study examines the implications of TRP against the step-wise evolution of drugs for cardiovascular conditions over the past 50 years. It illustrates the complex interactions between advances in understanding of cellular and molecular disease mechanisms, diagnostic techniques, treatment concepts, and the synthesis, testing and commercialisation of products. It confirms the highly unpredictable and incremental nature of the innovation process. Medical progress in terms of improvement in patient outcomes over the long-term depends on the cumulative effect of year after year of painstaking incremental advances. It shows that the parallel processes of advances in scientific knowledge and the industrial 'investment-innovative cycle' involve highly developed sets of complementary capabilities and resources. A framework is developed to assess the impact of TRP upon research and development investment decisions and the development of therapeutic classes. We conclude that a simple categorisation of products as either 'truly innovative' or 'therapeutically equivalent' is inconsistent with the incremental processes of innovation and the resulting differentiated product streams revealed by our analysis. Widespread introduction of TRP would probably have prematurely curtailed development of many incremental innovations that became the preferred 'product of choice' by physicians for some indications and patients in managing the incidence of cardiovascular disease.
authors: Imperial College Medical School, London, UK.
authors: Desmond
authors: D
authors: Sheridan
authors: Jim
authors: J
authors: Attridge
mesh_terms: D002317:Cardiovascular Agents / Q000191:economics* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000191:economics; D003365:Costs and Cost Analysis / Q000639:trends; D016527:Drug Costs / Q000639:trends*; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000639:trends; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000639:trends; D012051:Reimbursement Mechanisms; D012106:Research / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents
references: Health Policy. 1998 Apr;44(1):73-85
references: 10180203
references: Circulation. 1980 Nov;62(5):996-1010
references: 7418184
references: Pharmacoeconomics. 1998 Nov;14(5):471-9
references: 10344913
references: Pflugers Arch. 1969;312(1):R8-9
references: 5390309
references: Pharmacoeconomics. 1996;10 Suppl 2:75-80
references: 10163439
references: Lancet. 2002 Jul 6;360(9326):7-22
references: 12114036
references: Pharmacotherapy. 1985 May-Jun;5(3):109-26
references: 2991865
references: J Physiol. 1887 Feb;8(1):15-9
references: 16991451
references: Lancet. 1999 Jan 2;353(9146):9-13
references: 10023943
references: Lancet. 2000 Nov 25;356(9244):1784-5
references: 11117905
references: Br Heart J. 1978 Oct;40(10):1069-118
references: 361054
references: Science. 1976 Jan 16;191(4223):150-4
references: 174194
references: Br J Clin Pharmacol. 1983 Nov;16(5):557-60
references: 6139123
references: N Engl J Med. 1987 Jun 4;316(23):1429-35
references: 2883575
references: Am Heart J. 1994 May;127(5):1388-401
references: 8172070
references: Am J Physiol. 1948 Jun;153(3):586-600
references: 18882199
references: Health Policy. 1994 May;28(2):89-132
references: 10171936
references: Lancet. 1994 Nov 19;344(8934):1383-9
references: 7968073
references: Clin Cardiol. 1995 Jun;18(6):335-40
references: 7664508
references: N Engl J Med. 1998 Sep 3;339(10):693-8
references: 9725930
references: J Health Econ. 2003 Mar;22(2):151-85
references: 12606142
references: Lancet. 2003 Apr 5;361(9364):1149-58
references: 12686036
references: Clin Cardiol. 1995 Mar;18(3 Suppl I):I3-8
references: 7743696
references: Br J Pharmacol Chemother. 1965 Dec;25(3):577-91
references: 4380598
references: Pharmacoeconomics. 2004;22(2 Suppl 2):1-14
references: 15660473
references: N Engl J Med. 2000 Jan 20;342(3):145-53
references: 10639539
references: Pharmacoeconomics. 2004;22(2 Suppl 2):15-24
references: 15660474
references: Br Heart J. 1981 Apr;45(4):457-9
references: 7225259
references: Nature. 1967 May 6;214(5088):597-8
references: 6036174
references: Pharmacoeconomics. 1996;10 Suppl 2:110-23
references: 10163428
references: Lancet. 2004 Aug 21-27;364(9435):685-96
references: 15325833